Evogene Stock Price, News & Analysis (NASDAQ:EVGN)

$3.83 0.09 (2.41 %)
(As of 11/17/2017 01:45 AM ET)
Previous Close$3.74
Today's Range$3.71 - $4.00
52-Week Range$3.60 - $5.88
Volume12,513 shs
Average Volume13,546 shs
Market Capitalization$98.1 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6

About Evogene (NASDAQ:EVGN)

Evogene logoEvogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.


Industry, Sector and Symbol:
  • Industry: Agricultural Biotechnology
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:EVGN
  • CUSIP: N/A
  • Web: www.evogene.com
Debt:
  • Current Ratio: 17.67%
  • Quick Ratio: 17.67%
Sales & Book Value:
  • Annual Sales: $6.54 million
  • Price / Sales: 15.08
  • Book Value: $3.43 per share
  • Price / Book: 1.12
Profitability:
  • Trailing EPS: ($0.83)
  • Net Income: ($19,590,000.00)
  • Net Margins: -462.56%
  • Return on Equity: -24.88%
  • Return on Assets: -22.64%
Misc:
  • Employees: 240
  • Outstanding Shares: 25,750,000
 

Frequently Asked Questions for Evogene (NASDAQ:EVGN)

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) issued its quarterly earnings results on Thursday, August, 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.07. The biotechnology company had revenue of $3.82 million for the quarter, compared to analysts' expectations of $5.36 million. Evogene had a negative return on equity of 24.88% and a negative net margin of 462.56%. View Evogene's Earnings History.

When will Evogene make its next earnings announcement?

Evogene is scheduled to release their next quarterly earnings announcement on Wednesday, November, 22nd 2017. View Earnings Estimates for Evogene.

Who are some of Evogene's key competitors?

Who are Evogene's key executives?

Evogene's management team includes the folowing people:

  • Martin S. Gerstel, Chairman of the Board (Age 73)
  • Ofer Haviv, President, Chief Executive Officer (Age 47)
  • Alex Taskar, Chief Financial Officer
  • Yuval Ben-Galim, Chief Operating Officer
  • Hagai Karchi, Executive Vice President, Chief Technology Officer (Age 53)
  • Amos Shachar, Vice President of Project Management (Age 39)
  • Lea Slonim Bloom, Director of Administration & Human Resources (Age 43)
  • Sarit Firon, Director
  • Adina Makover, Director (Age 65)
  • Leon Yehuda Recanati, Director (Age 67)

Who owns Evogene stock?

Evogene's stock is owned by a variety of of retail and institutional investors. Top institutional investors include PHOENIX HOLDINGS LTD. (77.00%). View Institutional Ownership Trends for Evogene.

How do I buy Evogene stock?

Shares of Evogene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evogene's stock price today?

One share of Evogene stock can currently be purchased for approximately $3.83.

How big of a company is Evogene?

Evogene has a market capitalization of $98.1 million and generates $6.54 million in revenue each year. The biotechnology company earns ($19,590,000.00) in net income (profit) each year or ($0.83) on an earnings per share basis. Evogene employs 240 workers across the globe.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET, REHOVOT L3, 7612002. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]


MarketBeat Community Rating for Evogene (NASDAQ EVGN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  108
MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Evogene (NASDAQ:EVGN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Evogene (NASDAQ:EVGN)

Price Target History for Evogene (NASDAQ:EVGN)

Analysts' Ratings History for Evogene (NASDAQ:EVGN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/17/2016Credit Suisse GroupLower Price TargetOutperform$19.00 -> $10.00N/AView Rating Details
11/19/2015Piper Jaffray CompaniesLower Price TargetNeutral$12.00 -> $8.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Evogene (NASDAQ:EVGN)

Earnings by Quarter for Evogene (NASDAQ:EVGN)

Earnings History by Quarter for Evogene (NASDAQ EVGN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/22/2017($0.19)N/AView Earnings Details
8/10/20176/30/2017($0.13)($0.18)$1.18 millionViewN/AView Earnings Details
5/17/20173/31/2017($0.18)($0.19)$0.72 millionViewN/AView Earnings Details
2/27/2017Q4($0.18)($0.26)$1.18 millionViewListenView Earnings Details
11/21/2016Q3($0.07)($0.20)$1.54 millionViewN/AView Earnings Details
8/11/2016Q2($0.11)($0.18)$5.36 million$3.82 millionViewListenView Earnings Details
5/19/2016Q1($0.11)($0.13)$2.70 million$2.00 millionViewListenView Earnings Details
3/1/2016Q415($0.17)($0.22)$3.90 million$2.46 millionViewN/AView Earnings Details
11/18/2015Q315($0.15)($0.13)$3.50 million$3.31 millionViewListenView Earnings Details
8/5/2015Q215($0.19)($0.20)$4.40 million$2.66 millionViewN/AView Earnings Details
5/19/2015Q115($0.20)($0.13)$3.65 million$2.70 millionViewListenView Earnings Details
2/26/2015Q4($0.12)($0.19)$3.64 millionViewN/AView Earnings Details
11/10/2014Q314($0.10)($0.17)$4.20 million$3.16 millionViewN/AView Earnings Details
8/20/2014Q214($0.11)($0.13)$4.77 million$3.85 millionViewN/AView Earnings Details
5/7/2014Q1 14($0.13)($0.09)$5.40 million$3.86 millionViewN/AView Earnings Details
3/19/2014Q413($0.08)($0.20)$4.95 million$4.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Evogene (NASDAQ:EVGN)
Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS

Dividends

Dividend History for Evogene (NASDAQ:EVGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Evogene (NASDAQ EVGN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Evogene (NASDAQ:EVGN)

Latest Headlines for Evogene (NASDAQ EVGN)

Source:
DateHeadline
Comparing Evogene (EVGN) and Calyxt (CLXT)Comparing Evogene (EVGN) and Calyxt (CLXT)
www.americanbankingnews.com - November 17 at 11:25 PM
Contrasting Calyxt (CLXT) & Evogene (EVGN)Contrasting Calyxt (CLXT) & Evogene (EVGN)
www.americanbankingnews.com - November 17 at 11:24 PM
Financial Analysis: Evogene (EVGN) versus Calyxt (CLXT)Financial Analysis: Evogene (EVGN) versus Calyxt (CLXT)
www.americanbankingnews.com - November 17 at 5:22 AM
Critical Review: Calyxt (CLXT) vs. Evogene (EVGN)Critical Review: Calyxt (CLXT) vs. Evogene (EVGN)
www.americanbankingnews.com - November 16 at 9:34 PM
Evogene Ltd (EVGN) Set to Announce Quarterly Earnings on WednesdayEvogene Ltd (EVGN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 15 at 1:50 AM
Evogenes First Quarter 2016 Earnings Announcement ScheduleEvogene's First Quarter 2016 Earnings Announcement Schedule
www.thestreet.com - May 2 at 9:37 AM
Evogene reports 4Q lossEvogene reports 4Q loss
www.cnbc.com - March 1 at 2:48 PM
Evogenes Fourth Quarter And Full Year 2015 Earnings Announcement ScheduleEvogene's Fourth Quarter And Full Year 2015 Earnings Announcement Schedule
www.thestreet.com - February 9 at 12:05 PM
Insect-Beating Seeds Are Growth Engine for Evogene, CEO SaysInsect-Beating Seeds Are Growth Engine for Evogene, CEO Says
www.bloomberg.com - January 5 at 9:26 AM
CFO Moves: Benefitfocus Inc., EvogeneCFO Moves: Benefitfocus Inc., Evogene
blogs.wsj.com - December 22 at 4:51 PM

Social Media

Financials

Chart

Evogene (NASDAQ EVGN) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.